Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
11:51am, Tuesday, 17'th Dec 2024
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
09:16am, Tuesday, 17'th Dec 2024
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
08:30am, Tuesday, 17'th Dec 2024
BrightInsight announced an expanded global digital partnership with Sanofi to build branded patient apps to drive adoption, adherence, and persistence.
Teva, Sanofi say drug to treat IBD met primary targets
07:35am, Tuesday, 17'th Dec 2024
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
07:30am, Tuesday, 17'th Dec 2024
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co
Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
12:01pm, Friday, 13'th Dec 2024
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
05:54pm, Thursday, 12'th Dec 2024
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
11:25am, Wednesday, 11'th Dec 2024
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
01:00am, Wednesday, 11'th Dec 2024
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vac
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
02:06pm, Monday, 09'th Dec 2024
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MR
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
11:30am, Saturday, 07'th Dec 2024
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
08:00am, Friday, 06'th Dec 2024
HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of canc
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
01:30am, Friday, 06'th Dec 2024
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% controll
